Future trends in drugs for migraine prophylaxis

Research output: Contribution to journalArticle

Abstract

Migraine prevention hinges on a variety of non-specific drugs that mainly reduce neuronal hyperexcitability, the putative pathophysiological hallmark for migraine. The improved knowledge about migraine circuitry and neurobiology has prompted research to develop new specific migraine preventive medications targeted to innovative sites and mechanisms. Drugs designed to inhibit cortical spreading depression, for example tonabersat, might offer a useful option for the management of migraine with aura but not for migraine without aura. Inducible nitric-oxide synthase (iNOS) inhibition seems ineffective as a prophylactic strategy. Results are awaited from recent and ongoing phase II trials with glutamate receptor antagonists, third-generation antiepileptics, melatonin agonists, vitamin D3 and statins.

Original languageEnglish
JournalNeurological Sciences
Volume33
Issue numberSUPPL. 1
DOIs
Publication statusPublished - May 2012

Fingerprint

Migraine Disorders
Pharmaceutical Preparations
Cortical Spreading Depression
Migraine without Aura
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Migraine with Aura
Excitatory Amino Acid Antagonists
Neurobiology
Cholecalciferol
Nitric Oxide Synthase Type II
Melatonin
Anticonvulsants
Research

Keywords

  • Disability
  • Migraine
  • Prophylaxis
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Future trends in drugs for migraine prophylaxis. / Barbanti, Piero; Aurilia, Cinzia; Egeo, Gabriella; Fofi, Luisa.

In: Neurological Sciences, Vol. 33, No. SUPPL. 1, 05.2012.

Research output: Contribution to journalArticle

@article{97e1654602dd49ff873dfebaca702251,
title = "Future trends in drugs for migraine prophylaxis",
abstract = "Migraine prevention hinges on a variety of non-specific drugs that mainly reduce neuronal hyperexcitability, the putative pathophysiological hallmark for migraine. The improved knowledge about migraine circuitry and neurobiology has prompted research to develop new specific migraine preventive medications targeted to innovative sites and mechanisms. Drugs designed to inhibit cortical spreading depression, for example tonabersat, might offer a useful option for the management of migraine with aura but not for migraine without aura. Inducible nitric-oxide synthase (iNOS) inhibition seems ineffective as a prophylactic strategy. Results are awaited from recent and ongoing phase II trials with glutamate receptor antagonists, third-generation antiepileptics, melatonin agonists, vitamin D3 and statins.",
keywords = "Disability, Migraine, Prophylaxis, Treatment",
author = "Piero Barbanti and Cinzia Aurilia and Gabriella Egeo and Luisa Fofi",
year = "2012",
month = "5",
doi = "10.1007/s10072-012-1058-1",
language = "English",
volume = "33",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Future trends in drugs for migraine prophylaxis

AU - Barbanti, Piero

AU - Aurilia, Cinzia

AU - Egeo, Gabriella

AU - Fofi, Luisa

PY - 2012/5

Y1 - 2012/5

N2 - Migraine prevention hinges on a variety of non-specific drugs that mainly reduce neuronal hyperexcitability, the putative pathophysiological hallmark for migraine. The improved knowledge about migraine circuitry and neurobiology has prompted research to develop new specific migraine preventive medications targeted to innovative sites and mechanisms. Drugs designed to inhibit cortical spreading depression, for example tonabersat, might offer a useful option for the management of migraine with aura but not for migraine without aura. Inducible nitric-oxide synthase (iNOS) inhibition seems ineffective as a prophylactic strategy. Results are awaited from recent and ongoing phase II trials with glutamate receptor antagonists, third-generation antiepileptics, melatonin agonists, vitamin D3 and statins.

AB - Migraine prevention hinges on a variety of non-specific drugs that mainly reduce neuronal hyperexcitability, the putative pathophysiological hallmark for migraine. The improved knowledge about migraine circuitry and neurobiology has prompted research to develop new specific migraine preventive medications targeted to innovative sites and mechanisms. Drugs designed to inhibit cortical spreading depression, for example tonabersat, might offer a useful option for the management of migraine with aura but not for migraine without aura. Inducible nitric-oxide synthase (iNOS) inhibition seems ineffective as a prophylactic strategy. Results are awaited from recent and ongoing phase II trials with glutamate receptor antagonists, third-generation antiepileptics, melatonin agonists, vitamin D3 and statins.

KW - Disability

KW - Migraine

KW - Prophylaxis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84864260142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864260142&partnerID=8YFLogxK

U2 - 10.1007/s10072-012-1058-1

DO - 10.1007/s10072-012-1058-1

M3 - Article

C2 - 22644189

AN - SCOPUS:84864260142

VL - 33

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 1

ER -